Thank you. Good afternoon and good morning, everyone, depending on where you are. Very pleased to be joined today by Will Martin, the President and Chief Commercial Officer, Sten Gustafsson, our Director of IR and Strategy, and Sabina Berlin, our CFO. You can suspect I'm going to be making some forward-looking statements which I will highlight on slide two. On the next slide, I want to address some very significant recent events which can be summarized as following. We've been accelerating revenue growth during the first quarter, as we saw from the results, and are pleased that despite COVID, we have made significant progress, particularly in the U.S., where the access to the hospitals has been easier than the rest of the world. Critical progress has also been seen in the supply chain and manufacturing operations. We have been increasing both the quality and importantly, decreasing the cost of goods by influencing the manufacturing operations and now having an operation that manufactures parts of our products within here. We announced a couple of three weeks ago, a transition of leadership. The company, in my view, and the board's view, has now matured, addressed significant issues with the clinical, the manufacturing, and the regulatory. The focus, as we have been saying for quite some time, is now on commercialization. We all feel that Will, having now been alongside me for a long, long time, is the right person to lead the company in the next stage of commercial growth. Finally, we are in advanced conversations with the European Investment Bank regarding financial partnership. We've gone through a very extensive due diligence list, which we have received some very positive feedback and are discussing, as indicated, a potential for financial partnership with the EIB. On the next slide, I want to give some more color to what significant recent events mean and what do we mean by saying accelerating revenue growth. We increased sales from SEK 2.5 million in Q4 2020 to SEK 4 million in Q1 2021, and that represents about 60% of quarterly growth. The annual revenue growth from Q1 is at a 250% rate, and the global IRRAflow installed base has grown from 73 to 84. In addition, we actually shipped for the first time a revenue-generating Hummingbird globally, and that was the first international shipment. Despite, again, the COVID and all the restrictions with the pandemic, we are seeing a steadily increase in the interest and now revenue generation from our products. We made some critical progress in supply chain. As I said, we established in-house manufacturing and now have an FDA license after inspections that gives us the ability to then produce more products within our own facility. Finally, we have concluded the transition from G-MED to Dekra, which we view as a very substantial regulatory milestone. We discussed the leadership transition, and I want to highlight at the end that the discussions that I just mentioned with the European Investment Bank are in advanced stage. We have cleared the significant due diligence and are now discussing a potential framework for such a financial partnership. All in all, we're seeing a very strong quarter despite the pandemic. We're seeing the company getting further and more significantly, reaching a mature stage and focusing more and more on commercialization. We see now the beginnings of a significant uptake in our adoption rate and of course, revenue generation. With that, I'll turn it over to Sabina, who will cover the key financial data. Sabina. Thank you, Kleanthis. On slide four, I would like to highlight some of the financial data from the report. Kleanthis mentioned a revenue of SEK 4 million. We had an EBIT for the quarter of minus SEK 39.2 million. In this number, do take into account that we have a SEK 5 million one-off non-cash adjustment in inventory value. We have a reduction in production cost that reduces the value of inventory this quarter but will be beneficial to the COGS margin over the coming quarters. Earnings per share was minus SEK 0.59, and cash flow from operating activities minus SEK 34.4 million. We ended the quarter with liquid funds of SEK 397.7 million. I'd like to now hand it back over to Kleanthis. Kleanthis, would you like to continue on slide five? Yes. Thank you. I'd like to highlight the market size before I turn it over to Will to give us very significant details on the progress on the commercial front. Is that we are addressing a very significant market opportunity combined in over $1.7 billion between the intracranial bleeding market and the traumatic brain injury. This is, of course, only in the U.S. Globally, this exceeds a $2 billion market opportunity with very little innovation. We view and have now been verified with our interactions with some of the main stroke centers around the world that indeed, the need for innovative products like the ones IRRAS is offering is very, very strong. For us, it's a matter of utilizing the market as it is in our contacts by focusing more and more in the satisfying the demand for IRRAS, evaluations, ultimately conversions and revenue generation with the different hospitals around the world. A very large market. A market that really demands innovative products like the ones that we have. We are at the right stage now, assuming that a pandemic is going to ease across the globe, to be able to get significantly more traction in the commercial front. Let me turn it over to Will, who's going to take us through some of the distinctive features of our products and of course, talk about the recent developments in the commercial front. Will? Thank you, Kleanthis. Good afternoon, everybody. I'm excited to be here today to talk to you about the continued progress that IRRAS has shown during the first quarter. On slide seven, we'll start just with a brief product overview. As Kleanthis referenced, two innovative product lines to target the sizable neurocritical care market opportunity, starting off with IRRAflow, the world's first irrigating intracranial drainage system. Whereas other systems rely solely on passive gravity-driven drainage that are full of challenges and shortcomings, IRRAflow is introducing an active fluid exchange mechanism of action that not only provides needed gravity-driven drainage, but also adds in continuous pressure monitoring and automated irrigation. This fluid exchange process of irrigating and draining helps to keep drainage holes free from blockage formation, as well as diluting the surrounding toxic materials, making them easier to remove, enhancing overall patient treatment outcomes, and resulting in faster treatment times as well. On slide eight, this mechanism of action continues to be reinforced by our patient treatment outcomes. Now in more than 200 patient treatments globally, we've seen the impact of active fluid exchange. We've seen the impact of IRRAflow's irrigation by having no catheter occlusions thus far experienced when the system's active irrigation is employed. That compares quite favorably to the 47% occlusion rate with traditional external ventricular drainage. That overall system performance also anecdotally has been seen to be quite positive. Thus far, our patient treatments have resulted also in no major complications and also zero infections. The closed system design helps to minimize interaction with the outside world, minimizes the chance of potential bacteria introduction when treatment with IRRAflow is ongoing. While IRRAflow is the lead product that IRRAS was founded upon, we've since also expanded into the diagnostic side of traumatic brain injury, and that's outlined on slide nine with our Hummingbird product portfolio. Hummingbird uses a unique air bladder mechanism of action to calculate a patient's intracranial pressure. As brain tissue exerts pressure onto that air bladder, it's translated into a pressure reading and a pressure waveform. That mechanism of action and its external transducer results in an extremely accurate system that doesn't have error building upon itself hour after hour, because the system is now able to recalibrate itself after it's been inserted. This results in the most accurate commercially available ICP monitoring system, and it also results in something that's extremely easy to use and troubleshoot during the course of treatment. Not only do we have single lumen options, but Hummingbird product portfolio also with its Hummingbird Quad, offers the only system that provides four lumen, four functions within one access site to allow more efficient multimodal monitoring, where multiple parameters are measured at one time. It's a nice differentiating factor with the Hummingbird product portfolio. Moving on to slide 10, I'd first like to highlight the significant progress that's being made across the entire organization at IRRAS, setting the stage for continued commercial adoption. Kleanthis highlighted earlier the fact that we've now moved manufacturing of IRRAflow capital equipment into our own facility. This in-house manufacturing corresponds with approximately a 30% reduction in overall manufacturing costs. That manufacturing facility has now been inspected with zero findings by the U.S. FDA, as well as the California Department of Public Health to issue our required manufacturing license, and we'll continue to build and expand manufacturing of IRRAflow capital equipment in that facility for the remainder of this year. On top of that, other disposables for both IRRAflow and Hummingbird manufacturing partners are being consolidated. Fewer relationships for us to manage, and also the ability to drive better quality at a lower cost on the manufacturing side. Beyond manufacturing, Q1 was a very exciting quarter for us in terms of product development. First patient treatment occurred with our next generation enhanced IRRAflow catheter. You can see the pre and post images there from a patient that was treated at a new evaluation in North Carolina at Vidant Medical Center. This enhanced catheter provides similar drainage rates to our larger IRRAflow catheter with improved kink resistance, which allows it to be delivered in a better fashion, makes it much more user-friendly, and the feedback that we're getting from our customers on this next generation catheter has been quite positive so far. At the same time, the team is finalizing the rollout of our next generation IRRAflow control unit, continuing to look for ways to upgrade the software to enhance our overall nurse and physician training timelines, changing the way that the drainage bag is attached to the system to give more treatment flexibility, and now starting to incorporate the ability for IRRAflow to communicate with the centralized hospital monitoring system so that nurses can keep track of their IRRAflow patients even outside of the individual patient room. As a company focused on innovation and cutting edge solutions, it's important for us to continue this cadence of exciting product rollouts, listening to our customer feedback, and incorporating that into our product development pipeline. We were able to show meaningful progress on that during the first quarter. At the same time, we need to make sure that we continue to make our products available in markets across the world. On slide 12, we highlight the continued positive progress that we're making on the regulatory and quality front at IRRAS. Kleanthis referenced, and we announced earlier that we are in the process of transitioning our international regulatory services to a new notified body, the largest notified body in Germany, one of the leading notified bodies globally, Dekra. That process is now underway. Dekra has already completed very meaningful quality system audits for IRRAS under the new European Medical Device Regulations, ISO certification, as well as the MDSAP program. This Medical Device Single Audit Program is a critical step for us to be able to pursue needed product approvals, regulatory approvals in markets such as Australia, Brazil, Canada, and Japan moving forward. This MDSAP audit is an important step forward there. As we transition to Dekra, our IRRAflow CE marks will remain valid until 2024. The process is underway for Dekra to review the technical file for Hummingbird's CE mark. We're making progress on that front also. Finally, the key element in all of this is translating that positive momentum into meaningful clinical data that supports the superiority and use of our products, particularly IRRAflow. During the first quarter, a new publication from one of our newest customers, Buffalo General, was published as they outlined their initial experience with chronic subdural hematoma in the Cureus Journal of Medical Science. They've since also submitted a second case report for a bilateral intraventricular hemorrhage, the expectation is that will be published sometime during the second quarter. We're also pleased to report that the ventriculitis case series from Helsinki University Hospital has now been accepted for publication at another peer review journal, Operative Neurosurgery. Continuing to expand that base of evidence and that base of peer-to-peer usage of IRRAflow is a critical element of our strategy moving forward to document the system's performance in a variety of pathologies. On slide 14, we outlined the other important progress and areas of focus on the clinical front. The next step of clinical data generation is extremely important in growing our products commercially around the globe. During the first quarter, we're pleased to report that three clinical trials are now being initiated. The first one, the ACTIVE trial led by Aarhus University in Denmark, finalizing the protocol there to begin patient treatment in the very near future. This will be studying IRRAflow compared to traditional EVD treatments. One step beyond that, a partnership that we have with Helsinki University, as well as the clinical research team at Johns Hopkins University is following their earlier work on CLEAR III, looking at drainage when combined with thrombolytic medication. This will study IRRAflow, its irrigation, and tPA, a thrombolytic, compared to traditional EVD treatments with tPA alone. That will start to establish IRRAflow's effectiveness in the world of drug delivery. We're also beginning a registry, starting in the United States, to capture real-world data on the use of IRRAflow in the treatment of chronic subdural hematoma. Continuing to document system performance, reduced recurrence, shortened treatment time, continues to add data points to the story that we're discussing with customers on a regular basis. All of those elements combining together show that each of the functional groups within IRRAS is making important progress towards securing our long-term goals and shifting the focus of the organization towards commercial adoption as our primary focus. On slide 15, that also carries over to the finance side. As Kleanthis has referenced, as we announced in this morning's report, we do have ongoing conversations with the European Investment Bank about this partnership that can provide additional non-dilutive financing in the European Union to advance a lot of these clinical and product development projects. We expect those conversations to be finalized in coming weeks, and we look forward to sharing more on that front. On slide 16, I'll hand it back over to you briefly, Kleanthis, to discuss the previously announced leadership transition. Thank you, Will. As we said, I want to emphasize again what you just shared, that the fundamentals of the organization have been very solid and between the validation of product performance, bringing in in-house manufacturing, gaining some key regulatory approvals, the organization has been focusing in the past couple of quarters in building the execution abilities to both adopting and revenue generating of our products. We are at a stage where the time is right for Will to take over as the next leader of IRRAS. Obviously, Will brings a very strong commercial background and demonstrated skills. He's been a critical part of IRRAS for the last few years and working very closely with me to build a foundation that we think is now ready to take on a very expansive commercial enterprise. I'm very pleased to see Will into that position to lead the next stage of growth for IRRAS. Will? Thank you, Kleanthis. I'm excited for the opportunity. I've been working extremely closely with our broad IRRAS team members over the past year as the president of the organization. I think we are, based on a lot of these accomplishments that we just discussed, nicely positioned to continue to deliver revenue growth and shareholder value. We'll discuss that more on slide 17. You can see the revenue trajectory that we've experienced over the last handful of quarters. The announced revenue for the first quarter, SEK 4 million, is essentially double what we've experienced just within the past two quarters. We can see after the initial impact from the COVID-19 pandemic in the second quarter of last year, we returned to revenue growth in the third quarter. That's continued through the fourth quarter, and now showing the desired signs of acceleration entering into 2021. 60% quarter-over-quarter growth in SEK and all of the experience and activity of our team, particularly in the U.S., as things return to normal, continue to point towards additional growth moving forward. In the first quarter, our quarterly revenue was more than half of what we were able to accomplish on a yearly basis last year. Continuing to plant the necessary seeds and starting to see the return on that investment and the strategic decisions that we made through 2020. I'll highlight on slide 17 the fact that much of the revenue for the quarter of Q1 was driven from U.S. hospitals. That's expected as much of the commercial activity has returned to normalcy in the U.S. We were able to translate several important evaluations into commercial stocking orders during the first quarter. As vaccination programs begin to take hold in Europe and commercial activity can return to normal as restrictions wane, our expectation is those numbers will continue to grow as well. On slide 18, I think it's important to highlight the various commercial highlights from the first quarter. Across the board, we experienced broad revenue contribution from a variety of sources. Continuing even though travel is restricted, even though customer interaction is still impacted in Europe by the ongoing pandemic restrictions, we continue the expansion of our distribution partners to get systems into the marketplace, plant seeds for future growth. We're able to ship additional systems to new markets in the Middle East with Jordan, as well as additional countries and expanding partnerships in Europe with Austria, Italy, and other countries in Southeastern Europe. The lion's share of U.S. revenue was driven by disposable stocking orders from two new customers, two new comprehensive stroke centers that we've talked about before, Buffalo General and West Virginia University. In addition, as access returns to normal, we also generated additional IRRAflow revenue during the first quarter as a new evaluation at a new comprehensive stroke center, Vidant Medical Center in North Carolina, as that came on board. Growth with our direct hospitals in Europe continues. Revenue generated from our first Swedish hospital, Karolinska, there in Stockholm, placed a disposable order to support training and evaluation of the IRRAflow system. We continue to engage German hospitals as lockdown restrictions allow, and had additional German hospital come on board, the new German hospital that we hadn't worked with yet previously, Münster, to support an evaluation as training and patient treatments begin there. Beyond that, I think it's important to note that Q1 saw disposable reorders from five other U.S. accounts as well as two international distributors, showing continued product utilization and increased traction. Kleanthis referenced the first international revenue was generated from Hummingbird as we brought a new distributor on board in the Middle East. We continue to look for opportunities to drive a small amount of revenue with service from U.S. customers. All of the various buckets where we can drive revenue, we were able to experience during the first quarter with this broad revenue contribution. Along those same lines, we've now moved back into the growth of our commercial footprint to take advantage of this growing demand. In Europe, we now have five direct sales heads, during the first quarter, brought on an additional training resource. In the U.S., we have now grown to seven direct sales heads and four training resources, recently having brought on an additional territory manager and two new nurse educators to help with the training cycle. On slide 19 and 20, just want to discuss a handful of metrics that we continue to track. The global install base for IRRAflow continues to grow from 73 - 84 from the fourth quarter to the first quarter. That growth was driven by conversion of U.S. systems from evaluation to commercial systems, as well as additional systems that were shipped to our growing international network of distribution partners. Along the same lines, we will also now start to report and track the Hummingbird global install base. During the quarter, four additional Hummingbird control modules were installed as we initiated the first evaluations coming out of our Premier contract, as well as shipping the first Hummingbird systems internationally. The ultimate area of focus for us commercially is shown on slide 20. The key to revenue generation moving forward is converting interest, converting evaluations into commercial revenue-generating systems. In the first quarter, we more than doubled our commercial IRRAflow base in the U.S. Transitioning evaluations at Buffalo General and West Virginia University Medicine reduced the number of evaluation systems out there and also increased the number of commercial systems. Whereas we typically provide two, maybe three systems during an evaluation, as WVU Medicine and Buffalo General Medical Center came on board with the disposable placement agreements, they both requested additional systems to be able to treat more patients as their utilization and adoption grows. It was a very exciting quarter during the first quarter to see the impact of successful evaluations translate into the number of commercial systems as well as the revenue growth that was experienced. That was shown in the U.S. during the first quarter. Similar type of demand is being generated in Europe. We have systems in place at many of the key hospitals, many of the top neurosurgery centers in Europe, and are continuing to do remote training for these facilities and cautiously optimistic and having meaningful conversations with these facilities that in-person training and treatment support can begin as COVID-19 restrictions are reduced through the second quarter and members of our commercial support team become vaccinated. Queen Square, Karolinska, other places we've announced, Aarhus University, Helsinki. We've engaged Charité Berlin at this point. The focus in Europe is now also, as activity permits, transitioning interest into commercial demand, that'll be a key area of focus for us in the second quarter and beyond. Kleanthis, I'll hand it back over to you for slide 21. Thank you, Will. This is the last slide I want to highlight. We continue to deliver on our corporate milestones. We have demonstrated commercial production with revenue growth despite the pandemic. We have now, in several scientific publications, presented clinical evidence for severe pathologies with the use of IRRAflow. We received the approval in four different other markets. It is our goal for Hummingbird. Lastly, we continue to launch updates or new products or line extensions. We have already introduced the IRRAflow Laser Leveler, the Hummingbird Solo system, the next generation of catheter, and over the next couple of quarters, you're going to see the new IRRAflow Drainage Collection System, which further facilitates adoption of the IRRAflow system, particularly very popular with the nurses based on our interactions and our tests thus far. Finally, a very significant update in the software. We call that the IRRAflow Software 4.0. Again, increases the usability of the system. The company continues to deliver in terms of product development and with the sole focus to continue its growth and in revenue generation. We invite everyone to follow all of our developments. We have a number of things both in social media and otherwise. We have a podcast that you can hear surgeons talking about their experience with IRRAflow. This is on IRRAS Radio that you can find in Google and Apple apps. We have an IRRAS Academy app where you can see all of the details of our products and what difference they make in patients' lives. Of course, you can follow us on all social media from LinkedIn to YouTube and Twitter. With that, operator, we're very happy to open the forum for any questions there may be from the audience. Thank you. Thank you. Ladies and gentlemen, if you have a question for the speakers, please press zero one on your telephone keypad. Our first question comes from the line of Ulrik Trattner from Carnegie. Please go ahead. Your line is open. Thank you very much, and thanks for taking my question. First of all, sad that you're leaving, Kleanthis. Great that you will stay on the board of directors. Will Martin, great to see that you're progressing to CEO. Thank you. I'll just start off, it's quite encouraging to see that the conversion rate is increasing in terms of converting evaluation contracts to commercial contracts. If you could please help us out on just sort of the general timeframe, or if you can provide us with some additional granularity in terms of how long does it generally take before a hospital converts from an evaluation contract to a commercial contract, that would be very helpful. That's the first question, please. Yeah. In general terms, of course, the pandemic has increased those time frames, but we aim to typically six to nine months. As we interact more and more, we are finding ways to potentially shrink that timeframe further. Will, any additional comments? I think you hit it exactly right, Kleanthis. That's the expected timeline. I think as our experience with training the system and how to best set customers up for success and work with them to map out an evaluation, we're seeing those numbers go down. For instance, we just started an evaluation last week at Harbor UCLA, a stroke center in Los Angeles County. California had been locked down for approximately 12 months. We've been waiting to start this evaluation. We'd had continued conversations with the hospital on how to go about doing this. We ended up deciding upon a five-patient evaluation instead of a 10-patient evaluation or a 90-day evaluation as we typically see. Within the first week, we were able to treat the first couple of patients. I think that our main goal at this point, and while we're continuing to invest in these training and education resources, is to be able to move through these evaluations, these patient treatments faster, to get them to a buying decision. Great. Just looking at the sort of the two premier clinics that you have converted thus far during the quarter, Buffalo and West Virginia, are they looking to acquire more systems, or are their sort of needs fully satisfied? Do you have an approximation on how many patients they've treated thus far with IRRAflow? I would say that we're constantly looking at the number of systems placed at hospitals to make sure that we're not missing out on patient treatments. As I mentioned during the presentation, the enthusiasm from both WVU Medicine and Buffalo General Medical Center led them to request a larger number of systems from the beginning, we're seeing that translate into more patient treatments thus far. Keep in mind, when you're starting a launch, you're moving from training certain nurses and certain physicians into training the broader group. In both places, we absolutely aren't to the point where we feel that we've reached stability in terms of training. I can say, for instance, in their first month of having IRRAflow systems in their ICU, Buffalo General Medical Center has already been treating more than our goal of one patient a week. If I remember correctly, I think they treated seven patients just in April. We're continuing to move that in the same direction. West Virginia, their overall volume likely will not compare quite to Buffalo, just in terms of total patient volume. The level of engagement we've seen and the patient treatment success thus far still continues to move in the right direction. We actually started a new intraventricular patient treatment at West Virginia yesterday. Great. Thanks, Will. Just on the recent commercial conversions, have these all been with the latest software upgrades that you have launched? If so, how has this sort of implicated the adoption or ease of use by implementing the new software upgrades that you launched last quarter? We launched the new catheter last quarter, and each of these customers has the new catheter and are pleased with the results. We've not yet launched the new software. That is imminent. We've been working very closely with the nursing teams at each of our customers to provide the final pieces of feedback, and that will be our next product launch. That will be a key part of our messaging moving forward as to how this new enhanced interactive software helps to reduce that training time. That's something we're excited to share with everyone in the near future. Great. Thanks. Three short questions more, if I may. We can just start off with Hummingbird and the initial sort of adoption of clinics. Are these new clinics to IRRAS, or are these previous IRRAflow clinics that are intrigued to evaluate the Hummingbird? Both. We take a look at each hospital as we engage them, as we introduce IRRAS to the hospital to determine which products should be the lead products and which products they want to target first. We can point out a hospital like Our Lady of the Lake in Louisiana that purchased IRRAflow just prior to the start of COVID-19 in the first quarter of last year. We were essentially locked out of the hospital for a majority of the rest of the year due to access restrictions. When we were able to reengage the surgeons early this year, we unearthed the opportunity that they wanted to do more ICP monitoring as a standalone, and we're able to now pull Hummingbird through, and their evaluation of Hummingbird will get underway this quarter. We have other hospitals that we're now able to walk in and lead with Hummingbird, particularly ones within the Premier hospital network. I think the combination of IRRAflow and Hummingbird gives us the opportunity to tailor our approach based on the customer. Great. Thanks, Will. Obviously intriguing to hear that you have this new owned production facility for the controlled unit. Just out of curiosity, how big of a volume can you produce, and how long will it satisfy the demand out there, and when would you need to scale this up, and how hard would that be? Well, we've tailored our production at this point to be able to match our demand. I think it's just fair to say that we have plenty of capability to supply IRRAflow capital equipment for the foreseeable future. We have room within the facility to expand, and we'll watch closely demand and make sure that we're prepared to meet it. Our demand for 2021 and beyond, we can easily meet it through this facility, and we also have the ability and room to expand there moving forward, should we decide to bring other products in-house. That was a key part of the overall strategy of making sure that we retain flexibility and scalability. Kleanthis, anything you'd like to add there? Yeah. The other major and important things, of course, not only taking control of IRRAflow buildup, but because of some very significant and smart engineering, we have now been able to produce IRRAflow at 20% or closer, actually, to 25% cheaper. That's decreasing our cost of goods. It has an impact both on increasing the quality, but very significantly reducing our production cost. Great. Thank you, Kleanthis and Will. Just one last question, and perhaps this should be to Sabina then on the potential new venture loan from EIB and just the €7 to €9 million in combination with your current cash balance. First of all, what's the contingencies in order to obtain this loan from EIB, as well as do you believe that this will be enough to support your current commercial strategy, or do you expect additional financing to be needed? I can give a little bit of background about the EIB potential loan. It's structured in a way that we'll be able to pull tranches, and those will be connected to milestones set up by the EIB. The reason for that is that they want to continuously track the company's progress. We're through the due diligence process, and we're currently in what could be seen as a credit risk review stage, which is the final stages of this partnership approval structure. Kleanthis, do you want to give any comments on how this fits into the financial strategy? Yeah. At this point, obviously, the sole focus of the company is strengthening the commercial operations. We expect, of course, the lockdowns to ease in Europe. We have a good presence in Europe that we want to increase based on the demand that we're seeing. As we already explained, the company has laid a very strong foundation in the clinical engineering, R&D, and regulatory, so our commercialization is the sole focus, and that's how we're thinking about where do we invest our capital so that we can get the maximum return on that investment. It's clearly on the commercial front, given that we have the products and we see the demand. We just need to make sure that we have the presence to be able to educate and contact as many institutions as possible. Great. Thank you very much, everyone. That was all the questions on my end. Operator, can we see if there are other questions? I guess we covered most of the questions. I don't hear the operator, and there's a technical issue. Hearing none, we'd like to thank you for your attention and look forward to continuing to keep you posted for the progress that we're making, which we hopefully can continue with increased adoption rates and significantly growing revenue. Thank you all.